Weight and skeletal muscle loss with cabozantinib in metastatic renal cell carcinoma.

ABSTRACT:

Background

Cabozantinib, a standard of care metastatic renal cell carcinoma (mRCC), may be associated with weight and muscle loss. These effects of new generation VEGFR tyrosine kinase inhibitor on muscle mass loss are poorly described.

Methods

All cabozantinib-treated mRCC patients from January 2014 to February 2019 in our institution were included. Clinical data including weight were collected during therapy. Computed tomography images were centrally reviewed for response assessment, and axial sections at the third lumbar vertebrae were used to measure the total muscle area. Toxicities and cabozantinib outcomes were evaluated. Co-primary endpoints included skeletal muscle loss and weight loss (WL), longitudinally evaluated during treatment. WL has been classified according

SUBMITTER: Colomba E 

PROVIDER: S-EPMC9530538 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature